 Dear Reader, During his 16 years on CNBC's "Fast Money," Jon Najarian made some incredible calls… For instance, he personally invested in Facebook on IPO day… Before the stock climbed as high as 1,900%... He called Palantir a long-term buy on live TV back in 2020… Before it soared as high as 2,000%... And in early 2014, he put his neck out on the line on national TV recommending Tesla… Due to its groundbreaking "over the air" update technology and upcoming launch of the Model X, he told viewers that Tesla is NOT just a car company… Turns out, he was exactly right… And since then, Tesla stock has seen peak gains of 3,392%! But this "33X" call on Tesla might pale in comparison to Jon's newest prediction about Elon Musk… Because it has to do wfith Musk's historic SpaceX IPO… And a potential $44 TRILLION plan for what could be coming next. By making the simple moves Hall of Fame Trader, Jon Najarian will tell you about here… You could set yourself up for incredible wealth. Click here to see what Jon Najarian is predicting now.
Exclusive Article from MarketBeat.com
Medtronic Bottoms, Healthy Rebound AheadBy Thomas Hughes. Date Posted: 6/4/2026. 
Key Points
- Medtronic is on track to rebound in the back half of 2026.
- Solid results, cash flow, and dividends point to a shift in market sentiment.
- Institutions are buying, analysts remain optimistic, and catalysts are ahead.
- Special Report: 95% of SpaceX profits are already gone
Medtronic's (NYSE: MDT) primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty tied to macroeconomic pressures were evident in the company's June 3 earnings report, but the results were still inherently strong and expected to remain so. The likely impact on the share price is a move higher, as the market is deeply oversold and overdue for a rebound. The only question is how far the stock can climb, and the signs suggest that 25% upside is within easy reach.
Medtronic is trading within a long-term range, with critical resistance near $95. That level is more than 25% above the key support area, where MDT stock trades in early June. While lower prices remain a possibility, the reaction to MDT’s fiscal Q4 2026 earnings report suggests a bottom may be in place, and a rebound has already begun. 
Analysts and Institutions Reflect Confidence in MDT Capital ReturnAnalyst trends also suggest that a 25% stock price increase is an achievable target. Trends heading into the release were mixed, with numerous price target reductions, but the data show that analysts simply trimmed targets rather than making drastic changes. The net result is that while consensus declined modestly, it still points to robust 20% upside and the potential for fresh highs. The likely outcome is that the Q4 results will trigger renewed confidence in the company’s ability to generate cash flow, which is central to this story. Medtronic is a well-known dividend grower and is on track to be crowned a Dividend King. Q4 results included the 49th consecutive dividend increase, worth about 1.4% to investors, and put the company on track for inclusion in more indexes and greater institutional ownership, both potential catalysts for the share price. As it stands, the yield is about 3.5%, with shares near the low end of the trading range and valued at only 50% of the earnings outlook. The likely outcome is that Medtronic sustains growth over time, both in the business and in the dividend, although the pace may never be especially robust. Institutions signal confidence in the dividend and the company’s intrinsic value, owning more than 80% of the stock. Index-related holdings are high, but the ownership base is broad and still accumulating. MarketBeat data show six consecutive quarters of bullish behavior, including Q2 2026 so far. The likely outcome is that buying continues to build as institutions take advantage of the value-and-yield combination. Trading at 13 times this year’s earnings outlook, the stock is inexpensive relative to the S&P 500, offers nearly four times the yield of the S&P 500 Index Tracking ETF (NYSEARCA: SPY), and provides low-beta exposure to physical AI and the Internet of Things. Medtronic’s Portfolio Stands TallMedtronic had a good quarter, with revenue rising 9.9% to more than $9.8 billion. The top line came in 200 basis points (bps) better than expected, supported by strength across all segments. Cardiovascular led with a 10.1% gain, driven by a 78% increase in Cardiac Ablation Solutions, while diabetic care grew 8.1%, medical-surgical 5.1%, and neuroscience 3%. Margin trends were mixed, but the market was braced for much worse, as reflected in the downtrend in revisions ahead of the report. Adjusted diluted earnings declined 4.3% to $1.55, but that still represented a 65-basis-point outperformance and reflected enough cash flow and earnings to keep the balance sheet healthy. Guidance is another factor pointing to a strong move in the stock price. The company’s initial guidance for fiscal 2027 includes 7% organic revenue growth and slightly faster earnings growth. The bad news is that both targets came in slightly below consensus, but again, the market had been expecting worse. This year’s catalysts include the MiniMed (NASDAQ: MMED) spin-off. The initial IPO has been completed, with the final step expected later this year. In it, Medtronic will allow existing shareholders to exchange shares for MMED shares, effectively canceling one in favor of the other. The net result will be the distribution of the remaining 80% of MMED and a reduction in MDT shares. The move is also expected to lift net margins while enabling the more focused companies to execute their strategies more effectively. Medtronic’s risks remain unchanged. While recall risk and competition are constant concerns in the industry, the company also faces tariff threats and a growing need for cybersecurity. AI has changed the game in cybersecurity, introducing new challenges such as data poisoning. Incorrect, incoherent, or otherwise malicious data can have a devastating impact on AI models and agentic-influenced health outcomes.
This ad is sent on behalf of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482.
If you would like to unsubscribe from receiving offers for Market Rebellion, please click here.
. |
Tidak ada komentar:
Posting Komentar